Company type | Public |
---|---|
Nasdaq:
CERE Russell 2000 Component | |
Industry | Biopharmaceuticals |
Founded | 2018 |
Fate | Acquired by AbbVie (Pending) |
Headquarters | , United States |
Website |
cerevel |
Cerevel Therapeutics Holdings, Inc. is a biotechnology and pharmaceuticals company focused on the development of novel therapies for mental and neurological illnesses. [1] Cerevel was established in October 2018, and is headquartered in Cambridge, Massachusetts. [2]
The company was formed in a collaboration between pharmaceuticals company Pfizer and private equity firm Bain Capital. [3] [4]
In December 2023, AbbVie, an American pharmaceutical company, announced its intention to acquire Cerevel for US$8.7 billion. [5] [6] [7]
Cerevel uses novel approaches and technologies to develop its own drugs and treatment therapies. Its pipeline contains an array of drugs and therapies treating a range of conditions including Schizophrenia, Parkinson's, Epilepsy, mood disorders, and more. [8]
Notable Cerevel drugs and treatments at varying stages of development include:
Cerevel's tagline mission statement is to "unravel the mysteries of the brain" to treat neurological disease. [14] Scientifically, its approach to therapy development focuses on understanding the wiring of the brain, pursuing novel targets, and addressing specific receptor sub-types. [1]
The company has stated its approach to neurotherapy development can be viewed through three key lenses:
Company type | Public |
---|---|
Nasdaq:
CERE Russell 2000 Component | |
Industry | Biopharmaceuticals |
Founded | 2018 |
Fate | Acquired by AbbVie (Pending) |
Headquarters | , United States |
Website |
cerevel |
Cerevel Therapeutics Holdings, Inc. is a biotechnology and pharmaceuticals company focused on the development of novel therapies for mental and neurological illnesses. [1] Cerevel was established in October 2018, and is headquartered in Cambridge, Massachusetts. [2]
The company was formed in a collaboration between pharmaceuticals company Pfizer and private equity firm Bain Capital. [3] [4]
In December 2023, AbbVie, an American pharmaceutical company, announced its intention to acquire Cerevel for US$8.7 billion. [5] [6] [7]
Cerevel uses novel approaches and technologies to develop its own drugs and treatment therapies. Its pipeline contains an array of drugs and therapies treating a range of conditions including Schizophrenia, Parkinson's, Epilepsy, mood disorders, and more. [8]
Notable Cerevel drugs and treatments at varying stages of development include:
Cerevel's tagline mission statement is to "unravel the mysteries of the brain" to treat neurological disease. [14] Scientifically, its approach to therapy development focuses on understanding the wiring of the brain, pursuing novel targets, and addressing specific receptor sub-types. [1]
The company has stated its approach to neurotherapy development can be viewed through three key lenses: